The present disclosure relates to methods for extending the shelf life of a sterile ophthalmic pharmaceutical composition.

The present disclosure relates to methods for extending the shelf life of a sterile ophthalmic pharmaceutical composition.

A topical antiviral liquid for treatment of viral warts, which is a multi-component formula that contains a number of acids and salts in an aqueous solution, which liquid has been shown to have superior effectiveness in completely penetrating and removing wart tissue, while encouraging rapid regeneration of healthy tissue.

Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.

Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.

The present invention relates to a topical composition containing a probiotic and hyaluronic acid or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of inflammatory bowel disease.

The present invention relates to a topical composition containing a probiotic and hyaluronic acid or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of inflammatory bowel disease.

A composition comprising a hydrogen peroxide source and at least one salicylate. Preferably, the hydrogen peroxide source comprises hydrogen peroxide and a means for generating hydrogen peroxide.

A composition comprising a hydrogen peroxide source and at least one salicylate. Preferably, the hydrogen peroxide source comprises hydrogen peroxide and a means for generating hydrogen peroxide.

The present invention provides a pharmaceutical composition comprising the therapeutic peptide CyPep-1, for use in treating neoplastic lesions, in particular warts.